Alzamend Neuro Announces 1-For-10 Reverse Stock Split, Beginning With The Opening Of Trading On July 16, 2024
Alzamend Neuro Announces 1-For-10 Reverse Stock Split, Beginning With The Opening Of Trading On July 16, 2024
Alzamend Neuro, Inc. (NASDAQ:ALZN) ("Alzamend" or the "Company"), a clinical-stage biopharmaceutical company focused on developing novel products for the treatment of Alzheimer's disease ("Alzheimer's"), bipolar disorder ("BD"), major depressive disorder ("MDD") and post-traumatic stress disorder ("PTSD"), today announced that Alzamend's board of directors approved a one-for-ten reverse stock split of Alzamend's common stock ("Common Stock") that will be effective in the State of Delaware at 12:01 a.m. Eastern Time on July 16, 2024. Beginning with the opening of trading on July 16, 2024, the Company's Common Stock will trade on The Nasdaq Capital Market on a split-adjusted basis under the Company's existing trading symbol "ALZN". The new CUSIP number for the Common Stock will be 02262M506. The reverse stock split is part of the Company's plan to regain compliance with the Minimum Bid Price Requirement of $1.00 per share required to maintain continued listing on The Nasdaq Capital Market, among other benefits.
Alzamend Neuro公司（納斯達克股票代碼:ALZN）（“Alzamend”或“公司”）是一家臨床階段的生物製藥公司，致力於開發治療阿爾茨海默病(“阿爾茨海默病”)、雙相情感障礙(“BD”)、重度抑鬱症(“MDD”)和創傷後應激障礙(“PTSD”)的新藥產品。今天宣佈，Alzamend的董事會批准了一份一比十的逆向股票分割方案，將於2024年7月16日美國東部時間凌晨12:01在特拉華州生效。從2024年7月16日開始交易時段起，公司的普通股將在納斯達克資本市場上以公司現有的交易符號“ALZN”爲基礎進行拆分調整後交易。普通股的新CUSIP號碼爲02262M506。股票的逆向股份拆分是公司計劃恢復符合維持納斯達克資本市場上市所需每股1.00美元最低出價要求的一部分，以及其他好處。